Meeting
2018 Genitourinary Cancers Symposium
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
Authors
Matthew Raymond Smith
Massachusetts General Hospital Cancer Center/ Harvard Medical School, Boston, MA
Matthew Raymond Smith , Fred Saad , Maha Hussain , Cora N. Sternberg , Karim Fizazi , Karin Sayuri Yamada , Christian Kappeler , Iris Kuss , Bertrand F. Tombal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02799602
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS383)
DOI
10.1200/JCO.2018.36.6_suppl.TPS383
Abstract #
TPS383
Poster Bd #
P1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
First Author: Marc-Oliver Grimm
Poster
2022 ASCO Quality Care Symposium
Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).
First Author: Neal D. Shore
Poster
2021 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
First Author: Christian Gratzke
Poster
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
First Author: Neal D. Shore